Product Introduction :

Capmatinib is an oral, selective MET inhibitor developed by Novartis. In May 2020, it was approved by U.S. FDA for the treatment of adult patients of metastatic NSCLC with MET exon 14 skipping mutation (MET ex14). Capmatinib is the first drug for targeted therapy for the MET ex14 mutation.
The total incidence of MET 14 exon skipping mutation is 3%-6% in non-small cell lung cancer, 3%-4% in lung adenocarcinoma, and up to 22% in lung sarcomatoid carcinoma. Usually patients with this mutation have a poor prognosis and are not sensitive to chemotherapy, with poor efficacy. Capmatinib is a potent and selective MET inhibitor, and its inhibitory ability on MET is much stronger than that of other MET-targeted drugs such as crizotinib, etc.
Studies have shown that, in patients who have not received treatment and those who have previously received treatment (failed in one or two rounds of chemotherapy), the ORRs of Capmatinib were 67.9% and 40.6%, respectively, and Capmatinib provided durable response in all patients. The median duration of response in patients who received the initial treatment was 11.14 months and that in the patients who previously received treatment was 9.72 months.

Indications :

Capmatinib is indicated for the treatment of advanced non-small cell lung cancer (NSCLC) with MET exon 14 (MET ex14) skipping mutation.

Administration and Dosage :

Twice a day, 400 mg each time, for oral administration